Anti-IL-6 monoclonal antibody tocilizumab has shown efficacy in the treatment of systemic onset juvenile idiopathic arthritis induced MAS, and in cytokine launch syndrome after chimeric antigen receptor (CAR) T cell treatment for blood cancers58,59
Anti-IL-6 monoclonal antibody tocilizumab has shown efficacy in the treatment of systemic onset juvenile idiopathic arthritis induced MAS, and in cytokine launch syndrome after chimeric antigen receptor (CAR) T cell…